Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2010

View Archived Issues

Oncolytic vaccinia virus GL-ONC1 well tolerated in patients with solid cancers

Phase II trials assess Amgen's antibodies in pancreatic and non-small cell lung cancer

Continued benefit seen with 4-year odanacatib therapy in postmenopausal women

DHOdehase inhibitor LAS-186323 shows favorable safety and pharmacokinetics

Scientists identify potential biomarkers of delirium in ICU patients

FDA approves subcutaneous administration of Gamunex-C in primary immunodeficiency

Cytheris begins phase II EraMune 01 trial of CYT-107 in HIV-infected patients

BioMarin Pharma launches program for BMN-111 in the treatment of achondroplasia

Takeda submits azilsartan medoxomil MAA for essential hypertension

Agensys and Seattle Genetics begin phase I trial of ASG-5ME in prostate cancer

Pearl Therapeutics raises funds for phase II PT-003 program

Sigma-Tau describes new inhibitors of fatty acid amide hydrolase

Transcept Pharma presents preliminary data from Intermezzo driving study

Diamyd reports data from 4-week observation period in phase I NP-2 trial

Bristol-Myers Squibb claims new inhibitors of gamma-secretase

Intercell and Romark to begin phase II trial of IC-41/nitazoxanide combination in hepatitis C

Protege phase III trial of teplizumab does not meet primary efficacy endpoint

New anticancer agents identified by sanofi-aventis

Gruenenthal presents new bradykinin B1 receptor antagonists

Shionogi-ViiV Healthcare begins phase III program for HIV integrase inhibitor

Photocure enters into agreement with Salix Pharma for photodynamic colorectal diagnostic

EMA initiates review of Orion's centralized MAA for dexmedetomidine

Cytos Biotechnology collaborates with NIH and SAIC for malaria vaccines

Helix BioPharma reports data from phase II topical interferon alfa-2b trial

Phase I results reported for APD-916 in narcolepsy with cataplexy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...